Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Thursday at a closing price of $0.98, with 2.72 million shares of worth about $2.67 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 67.83% during that period and on June 27, 2024 the price saw a gain of about 17.96%. Currently the company’s common shares owned by public are about 227.17M shares, out of which, 226.10M shares are available for trading.
Stock saw a price change of 12.37% in past 5 days and over the past one month there was a price change of -5.69%. Year-to-date (YTD), ADAP shares are showing a performance of 23.68% which increased to 8.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.42 but also hit the highest price of $2.05 during that period. The average intraday trading volume for Adaptimmune Therapeutics Plc ADR shares is 1.49 million. The stock is currently trading -0.26% below its 20-day simple moving average (SMA20), while that difference is down -6.95% for SMA50 and it goes to 4.36% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) currently have 227.17M outstanding shares and institutions hold larger chunk of about 52.00% of that.
The stock has a current market capitalization of $250.59M and its 3Y-monthly beta is at 2.27. It has posted earnings per share of -$0.73 in the same period. It has Quick Ratio of 2.81 while making debt-to-equity ratio of 0.97. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADAP, volatility over the week remained 7.22% while standing at 6.80% over the month.
Stock’s fiscal year EPS is expected to drop by -640.61% while it is estimated to increase by 7.00% in next year. EPS is likely to shrink at an annualized rate of 1.00% for next 5-years, compared to annual growth of 10.30% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on May 30, 2024 offering a Sector outperform rating for the stock and assigned a target price of $3.15 to it. Coverage by Bryan Garnier stated Adaptimmune Therapeutics Plc ADR (ADAP) stock as a Buy in their note to investors on March 24, 2023, suggesting a price target of $3.60 for the stock. On January 03, 2023, Guggenheim Upgrade their recommendations, while on November 09, 2022, Mizuho Upgrade their ratings for the stock with a price target of $9. Stock get an Underweight rating from Barclays on May 28, 2021.
